The Clinical Significance Of GlyoxalaseⅠLevel In Serum In Type2Diabetic Mild Cognitive Impairment

[Objective]1. To observe in patients with type2diabetes with mild cognitivedysfunction1(Glyoxalase, GLO) changes glyoxylase explore GLO in type2diabeticpatients with mild cognitive impairment (Mild cognitive impairment) in the clinicalsignificance.[Methods] Select from June2013to April2014at Union Hospital of Fujian MedicalUniversity, Department of Endocrinology hospitalized patients with type2diabetes,42and 28non-diabetic patients were hospitalized in the Department of Neurology, divided into fourgroups:Group1diabetes with mild cognitive impairment group:20patients, mean age(60.14±6.49) years old, male11, female9;2diabetes group without mild cognitiveimpairment:22cases (mean age59.20±5.58) years old, male11, female11, threenon-diabetic group with mild cognitive impairment group:13cases, mean age (60.33±6.22)years old, seven men, six women;4groups non-diabetic patients without mild cognitiveimpairment group:15patients, mean age (57.85±4.93) years old, male7female8..Subjectsin each group to collect clinically relevant data such as BMI (Body Mass Index BMI): Weight(kg)/height2(m2); blood pressure; course; glucose: fasting plasma glucose (Fastingblood-glucose FBG), glycosylated hemoglobin (Glycosylated hemoglobin HbA1c); lipids:triglycerides (triglyceride TG), cholesterol (cholesterin CHOL), high density lipoproteincholesterol (high density lipoprotein cholesterol HDL-C), low density lipoprotein cholesterol(low density lipoprotein cholesterol LDL-C) etc., and enzyme-linked immunosorbent assay(ELISA) was measured GLO, AGEs, sRAGE levels. Using SPSS17.0statistical softwarefor statistical analysis, measurement data using completely randomized design single-factoranalysis of variance (ANOVA), correlation analysis using linear correlation, comparing thedifferences between each set of indicators and correlations.[Results]1. Clinical data: each group ANOVA showed: Age (P=0.656), BMI (P=0.477) there was no significant difference between the groups; duration, systolic anddiastolic blood pressure were significantly different between the three groups (P <0.05):where, l group, systolic blood pressure were significantly higher than group2group3and4,there was a significant difference (P <0.05);12,3,4systolic blood pressure were higher thangroup there was a significant difference (P <0.05); while systolic blood pressure differencebetween the two groups with3,4groups was not statistically significant (P=0.764, P=0.560). A group diastolic blood pressure higher than3,4group, there was a significantdifference (P <0.05);1and diastolic blood pressure between the two groups showed nosignificant difference (P=0.075),2groups of3,4diastolic differences between groups nostatistically significant (P=0.255, P=0.166). Between3,4systolic blood pressure, diastolicblood pressure was no significant difference (P=0.781, P=0.780).2. Univariate analysis of variance showed a group GLO serum levels were significantly reduced.(1group196.32±20.07ng/ml,2group229.61±41.47ng/ml,3group319.76±56.08ng/ml,4group289.12±84.98ng/ml; P <0.01); sRAGE serum levels while alsosignificantly reduced (group1515.73±313.16ng/l,2group828.49±313.16ng/l,3group1534.50±559.36ng/l,4group1486.75±571.92ng/l; P <0.01); while one group wassignificantly higher serum levels of AGEs (a group of1965.12±205.30,2group1717.98±187.67ng/ml,3groups1011.98±141.18ng/ml,4groups1045.06±159.69ng/ml; P <0.01)3. Pearson correlation analysis of AGEs, GLO, sRAGE between epidemiological andbiochemical indicators show: AGEs and Chol, LDL-C, TG, fasting glucose, systolic bloodpressure, diastolic blood pressure positively correlated with GLO, sRAGE, HDL-Cnegatively correlated; GLO-1and AGEs, Chol, LDL-C, TG, fasting glucose, systolic bloodpressure negatively correlated with sRAG, HDL-C positive correlation; sRAGE and AGEs,LDL-C, TG, fasting plasma glucose, systolic blood pressure negatively correlated positivelycorrelated with GLO.[Conclusion]1.Diabetic patients with mild cognitive impairment GLO-1in serum wassignificantly decreased and correlated with serum AGEs, sRAGE levels, suggesting thatGLO-1may play a role in suppressing the occurrence of diabetes, cognitive dysfunction anddevelopment.